PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth while GNPX is at 63.60%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-26.14%
Negative operating income growth while GNPX is at 63.60%. Joel Greenblatt would press for urgent turnaround measures.
-26.43%
Negative net income growth while GNPX stands at 63.93%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-26.52%
Negative EPS growth while GNPX is at 66.81%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-26.52%
Negative diluted EPS growth while GNPX is at 66.80%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x GNPX's 8.61%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.09%
Diluted share reduction more than 1.5x GNPX's 8.64%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while GNPX is at 52.72%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.72%
Negative FCF growth while GNPX is at 52.86%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
12.78%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
32.48%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-18544.23%
Negative 10Y net income/share CAGR while GNPX is at 56.02%. Joel Greenblatt sees a major red flag in long-term profit erosion.
7.55%
Below 50% of GNPX's 56.02%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
44.34%
3Y net income/share CAGR 75-90% of GNPX's 56.02%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1862.49%
Equity/share CAGR of 1862.49% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
309.42%
Equity/share CAGR of 309.42% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-81.93%
Negative 3Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D dropping or stable vs. GNPX's 333.47%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
24.63%
We expand SG&A while GNPX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.